Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: Results from a randomised placebo-controlled clinical trial

International Journal of Clinical Practice

Volumn 62, Issue 6, 2008, Pages 896-904

  Paolini, J F ^a   Mitchel, Y B ^a   Reyes, R ^a   Thompson Bell, S ^a   Yu, Q ^a   Lai, E ^a   Watson, D J ^a   Norquist, J M ^a   McCrary Sisk, C ^a   Bays, H E ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; NIACIN; QUESTIONNAIRES; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 43749087586     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01739.x     Document Type: Article

References (10)

1. The coronary drug project. JAMA 1972 221 : 918.
2. Capuzzi DM, Morgan JM, Brusco OA Jr., Intenzo CM. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000 2 : 64 71.
3. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004 62 : 229 34.
4. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998 82 : 29U 34U.
5. Mills E, Prousky J, Raskin G et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003 3 : 4 11.
6. Abbott Laboratories. Niaspan (Niacin Extended-Release Tablets) US Prescribing Information. Copyright 2007. http://www.niaspan.com/pdf/niaspan.pdf (accessed March 2008).
7. Andrade SM, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995 332 : 1125 31.
8. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aut 1996 164 : 208 11.
9. Abughosh SM, Kogut SJ, Andrade SE, Larrat EP, Gurwitz JH. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004 10 : 404 11.
10. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Development and validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007 23 : 1549 60.